Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2HIdGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP MXrTRW5ITVJ?
CAL-51 cell MmHPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7pSHlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJ4IH7N NX;pW|VtW0GQR1XS
ABC-1 cell NIjBOmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXfXOJFsUW6qaXLpeIlwdiCxZjDoeY1idiCDQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZ3IH7N NXTrSYczW0GQR1XS
A2780 cell M3PhUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? NELCRppUSU6JRWK=
ES1 cell NX3LVlg{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1nVdmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NIm0OpFUSU6JRWK=
HUTU-80 cell MmjtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2n5PWlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzlzIH7N NHfyUmlUSU6JRWK=
NCI-H292 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4XWc2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6NjDuUS=> NEHaNHlUSU6JRWK=
NB69 cell MoXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlXnTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yNkBvVQ>? M3HTUnNCVkeHUh?=
ES8 cell NWjS[pJKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\ROJA{UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMzKG6P NEfucYRUSU6JRWK=
BCPAP cell M1XpW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlTTTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Qhdk1? Mnn2V2FPT0WU
T-24 cell NFj1U41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O MnrVV2FPT0WU
EW-16 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVH6bYRxUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjFibl2= MliwV2FPT0WU
OVCAR-5 cell NYi1VmFoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYS4VW9vUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=> M3HDbnNCVkeHUh?=
SF126 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX:yW5JyUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTVibl2= MljBV2FPT0WU
KP-4 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlS2TY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6xO{BvVQ>? M1TUVXNCVkeHUh?=
GAMG cell NGTtNJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfJTY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NUBvVQ>? NGTSfpJUSU6JRWK=
HOS cell M1LWWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH3xepdKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVMhdk1? NUniSm9FW0GQR1XS
CHL-1 cell M1T3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWX5d45TUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDFibl2= NX7ZOoROW0GQR1XS
AGS cell M4L4O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NE\5ZpVKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFYhdk1? MnHIV2FPT0WU
MDA-MB-157 cell Ml\OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N NFfFfIVUSU6JRWK=
HSC-3 cell MoWyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1fsd2lvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAzKG6P NFrIdo9USU6JRWK=
CAL-72 cell NHPIPFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrHV3pKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NIXqRmFUSU6JRWK=
NBsusSR cell M2\UXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGLmdnlKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF|IH7N MVrTRW5ITVJ?
ES7 cell NEDudHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;NTmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61PUBvVQ>? NWPNV2ZqW0GQR1XS
H-EMC-SS cell NF;6UmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1Xse2lvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N MoX5V2FPT0WU
NCI-H1703 cell MnTWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnnTTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N Ml;NV2FPT0WU
BHT-101 cell MlT0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\ETY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?= NFHE[5lUSU6JRWK=
SK-OV-3 cell NVu1UXlZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2TRWmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzVibl2= MUjTRW5ITVJ?
EW-24 cell MkjSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MojyTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? NVjjNFNGW0GQR1XS
PSN1 cell M{POcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3nmVGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFQhdk1? MWrTRW5ITVJ?
OVCAR-8 cell M4HCW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37XSGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= M1XqWnNCVkeHUh?=
NCI-H1563 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmfDTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF|IH7N M4nKZ3NCVkeHUh?=
SW756 cell M2LvV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? M1LHVHNCVkeHUh?=
A375 cell Ml;uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3z0OGlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVQhdk1? MmWzV2FPT0WU
Ca9-22 cell M{SxZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\5U4xKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOjVibl2= Moq4V2FPT0WU
SW1990 cell M4nUc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;XTY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P M{nVcHNCVkeHUh?=
ES4 cell NXzuNopQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwM{mgcm0> NFiyW3RUSU6JRWK=
HCE-T cell NHrwSnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnoemtKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PSCwTR?= NU\mbJJKW0GQR1XS
MOLT-16 cell NF;aOXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlU{KG6P MnTGV2FPT0WU
HSC-4 cell NHvWNZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrlOGtKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE45KG6P MWXTRW5ITVJ?
NCI-SNU-1 cell NXzrVmdoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoezTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njh4IH7N M{jpWnNCVkeHUh?=
EW-11 cell NYTlWZlyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnrvTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPUBvVQ>? NF\QdFZUSU6JRWK=
HT-1080 cell NYDHe4YxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmrSTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QSCwTR?= MYPTRW5ITVJ?
MES-SA/Dx5 cells MYjDfZRwfG:6aXPpeJkh[XO|YYm= MlPoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczygTWM2OD13IH7N MoDlNlM6Ozd7OEG=
SW1710 cell NE\tOYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojnTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlE3KG6P M{XiO3NCVkeHUh?=
EW-1 cell Ml\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIPHZ4lKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P MmS0V2FPT0WU
BV-173 cell NUjqXVU1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXjXV2RUUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7IH7N MlfWV2FPT0WU
TE-8 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPUTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60NUBvVQ>? MnPlV2FPT0WU
G-401 cell M3P6VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoK0TY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFMhdk1? NXrJfWZsW0GQR1XS
KOSC-2 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;k[mlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?= NGX0TpNUSU6JRWK=
HuCCT1 cell M2SyWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUTJcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? NWrCVXdZW0GQR1XS
FADU cell M3rRTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfwOGlKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P NW\KOoFWW0GQR1XS
MHH-ES-1 cell Mn;jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QSCwTR?= NFTZfXZUSU6JRWK=
ES3 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUXMSYdTUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6KG6P MWfTRW5ITVJ?
OVCAR-4 cell NWi1WGU6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUTYWHBIUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> M1TNRXNCVkeHUh?=
HD-MY-Z cell MonNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYHSVVZkUW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57MTDuUS=> MojCV2FPT0WU
human JAR cell NXLpO3l7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH7mWodKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? MYrTRW5ITVJ?
A427 cell M4[5Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVK2TJdvUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xPyCwTR?= NUnuXW04W0GQR1XS
697 cell M4nje2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITFb|hKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVMhdk1? NF7jSIhUSU6JRWK=
OVCAR-3 cell M2XOVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{DhSGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOiCwTR?= NX\hb2l2W0GQR1XS
human NB14 cell M1HxRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEjDW5VKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P MWPTRW5ITVJ?
GB-1 cell NVTMTmdpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVW2bZpKUW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?= MVXTRW5ITVJ?
COR-L105 cell NGjKN3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHziWJJKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi55NjDuUS=> NFXEXHVUSU6JRWK=
647-V cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj65JI5O MUDTRW5ITVJ?
human K5 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\OW4ZKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NzDuUS=> NISwWVdUSU6JRWK=
DMS-273 cell MlyxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1izbGlvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUK3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2= NVvncFlRW0GQR1XS
UM-UC-3 cell NV;BSWdyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF3rU|BKdmirYnn0bY9vKG:oIHj1cYFvKFWPLWXDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N NXzyPXlTW0GQR1XS
HEL cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHQTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkC4JI5O NVW0XFR6W0GQR1XS
human KU-19-19 cell NVrWcphWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xQSCwTR?= NHP2e4FUSU6JRWK=
MC-IXC cell MlLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNVchdk1? MU\TRW5ITVJ?
human H4 cell NYfsVHdpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DhOmlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkK1JI5O M3[zVnNCVkeHUh?=
NUGC-3 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnHTY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P MXTTRW5ITVJ?
CHP-212 cell NGfNOFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVnkPVJTUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|NDDuUS=> M2LZNnNCVkeHUh?=
human SW982 cell M3q2UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HmRmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P M{CzWnNCVkeHUh?=
C-33-A cell MlKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVghdk1? M1\vbHNCVkeHUh?=
PC-3 cell NH;rTXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF\zU3JKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg6KG6P Ml3HV2FPT0WU
COLO-684 cell M3zMcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPnOVRKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS5{MTDuUS=> NX7xWYxyW0GQR1XS
SNU-387 cell MlSzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2DuRmlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2= MmixV2FPT0WU
U251 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3rMZWlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? MljuV2FPT0WU
A673 cell Mn7DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn32TY5pcWKrdHnvckBw\iCqdX3hckBCPjd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuOkBvVQ>? NXXZWnZ4W0GQR1XS
human T47D cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXnTWG9oUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2= NXSzdpVCW0GQR1XS
A549 cell NYeyXXdGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2LZbWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlYhdk1? M3HxXHNCVkeHUh?=
PC-14 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYXJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuO|Mhdk1? NHO0VppUSU6JRWK=
A704 cell MlrGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jTdmlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK3MlQ2KG6P MXXTRW5ITVJ?
MCF7 cell NX;M[Hd5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|MT6zOkBvVQ>? M4HLRnNCVkeHUh?=
PC3 cells MXnGeY5kfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKFCGS{GtcYVlcWG2ZXSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCWaIKzNFghemW|aXT1[UBqdiCqdX3hckBRSzNiY3XscJMh[nliRVzJV2EtKEmFNUC9NE4yOTNizszN MUKyNVM1OTZ5NR?=
F-36P cells MVnQdo9tcW[ncnH0bY9vKGG|c3H5 NHjCPYVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF[tN|ZRKGOnbHzzMEBKSzVyPUCuNlgh|ryP M4fzNVIyOzRzNke1
OCI-AML2 cells NGDHc2xRem:uaX\ldoF1cW:wIHHzd4F6 NFLnNHFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN NGPCOXYzOTN2MU[3OS=>
K562 cells M4H6XnBzd2yrZnXyZZRqd25iYYPzZZk> NUTOdHdKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? NELD[VYzOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID